Chimeric antigen receptor-modified macrophages trigger systemic anti-tumour immunity.
Animals
Breast Neoplasms
/ immunology
Disease Models, Animal
Female
Genes, Reporter
HEK293 Cells
Humans
Immunity, Innate
Immunotherapy, Adoptive
Lipid Droplets
/ immunology
Macrophages
/ immunology
Mice
Mice, Inbred BALB C
RAW 264.7 Cells
Receptors, CCR7
/ genetics
Receptors, Chimeric Antigen
/ genetics
Spleen
/ immunology
Thymus Gland
/ immunology
c-Mer Tyrosine Kinase
/ genetics
adoptive cell therapy
breast cancer
macrophage
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
14
05
2020
revised:
16
09
2020
accepted:
29
10
2020
pubmed:
4
11
2020
medline:
9
6
2021
entrez:
3
11
2020
Statut:
ppublish
Résumé
Preliminary results and emerging data have shown that lipid droplet high (LD
Substances chimiques
CCR7 protein, human
0
Receptors, CCR7
0
Receptors, Chimeric Antigen
0
MERTK protein, human
EC 2.7.10.1
c-Mer Tyrosine Kinase
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-257Informations de copyright
© 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Références
Poggio M, Hu T, Pai CC, et al. Suppression of exosomal PD-L1 induces systemic anti-tumour immunity and memory. Cell 2019; 177: 414-427.e13.
Han Y, Liu Q, Hou J, et al. Tumour-induced generation of splenic erythroblast-like Ter-cells promotes tumour progression. Cell 2018; 173: 634-648.e12.
Mauffrey P, Tchitchek N, Barroca V, et al. Progenitors from the central nervous system drive neurogenesis in cancer. Nature 2019; 569: 672-678.
Engblom C, Pfirschke C, Zilionis R, et al. Osteoblasts remotely supply lung tumours with cancer-promoting SiglecFhigh neutrophils. Science 2017; 358: eaal5081.
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1-10.
Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40: 2969-2975.
Zhang Y, Kurupati R, Liu L, et al. Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumour microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell 2017; 32: 377-391.e9.
Veglia F, Tyurin VA, Mohammadyani D, et al. Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nat Commun 2017; 8: 2122.
Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, et al. ER stress sensor XBP1 controls anti-tumour immunity by disrupting dendritic cell homeostasis. Cell 2015; 161: 1527-1538.
Herber DL, Cao W, Nefedova Y, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 2010; 16: 880-886.
Niu Z, Shi Q, Zhang W, et al. Caspase-1 cleaves PPARγ for potentiating the pro-tumour action of TAMs. Nat Commun 2017; 8: 766.
Veglia F, Tyurin VA, Blasi M, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature 2019; 569: 73-78.
Li P, Lu M, Shi J, et al. Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis. Nat Immunol 2020; 21: 1444-1455.
Morsut L, Roybal KT, Xiong X, et al. Engineering customized cell sensing and response behaviors using synthetic Notch receptors. Cell 2016; 164: 780-791.
Alvey CM, Spinler KR, Irianto J, et al. SIRPA-inhibited, marrow-derived macrophages engorge, accumulate, and differentiate in antibody-targeted regression of solid tumours. Curr Biol 2017; 27: 2065-2077.e6.
Lee S, Kivimäe S, Dolor A, et al. Macrophage-based cell therapies: the long and winding road. J Control Release 2016; 240: 527-540.
Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell 2017; 168: 724-740.
Jordan MS. Genetic reconstitution of bone marrow for the study of signal transduction ex vivo. Methods Mol Biol 2006; 332: 331-342.
Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010; 16: 133-144.
Zhang Q, Hwang JW, Oh JH, et al. Effects of the fibrous topography-mediated macrophage phenotype transition on the recruitment of mesenchymal stem cells: an in vivo study. Biomaterials 2017; 149: 77-87.
Fu X, Tao L, Rivera A, et al. A simple and sensitive method for measuring tumour-specific T cell cytotoxicity. PLoS One 2010; 5: e11867.
Karimi MA, Lee E, Bachmann MH, et al. Measuring cytotoxicity by bioluminescence imaging outperforms the standard chromium-51 release assay. PLoS One 2014; 9: e89357.
Roberts EW, Broz ML, Binnewies M, et al. Critical role for CD103+/CD141+ dendritic cells bearing CCR7 for tumour antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 2016; 30: 324-336.
Sharma N, Benechet AP, Lefrançois L, et al. CD8 T cells enter the splenic T cell zones independently of CCR7, but the subsequent expansion and trafficking patterns of effector T cells after infection are dysregulated in the absence of CCR7 migratory cues. J Immunol 2015; 195: 5227-5236.
Shields JD, Fleury ME, Yong C, et al. Autologous chemotaxis as a mechanism of tumour cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 2007; 11: 526-538.
Shields JD, Kourtis IC, Tomei AA, et al. Induction of lymphoidlike stroma and immune escape by tumours that express the chemokine CCL21. Science 2010; 328: 749-752.
Zhou S, Chen L, Qin J, et al. Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumour immunity. PLoS One 2013; 8: e73952.
Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008; 8: 362-371.
Davalos-Misslitz AC, Rieckenberg J, Willenzon S, et al. Generalized multiorgan autoimmunity in CCR7 deficient mice. Eur J Immunol 2007; 37: 613-622.